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Key Points: 
Avadomide induces type I and II IFN signaling in T cells, triggering a feedforward cascade of 
reinvigorated anti-CLL immune responses  
 
IFN-driven promotion of a CD8+ T cell-inflamed microenvironment by avadomide enhances anti-PD-
L1/PD-1 efficacy in pre-clinical models 
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Abstract 
 
Cancer treatment has been transformed by checkpoint blockade therapies, with the highest anti-tumor 
activity of anti-programmed death 1 (PD-1) antibody therapy seen in Hodgkin lymphoma (HL). 
Disappointingly, response rates have been low in the non-Hodgkin lymphomas (NHLs), with no activity 
seen in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) with PD-1 blockade. Thus, 
identifying more powerful combination therapy is required for these patients. Here, we pre-clinically 
demonstrate enhanced anti-CLL activity following combinational therapy with anti-PD-1 or anti-PD-1 
ligand (PD-L1) and avadomide, a cereblon E3 ligase modulator (CELMoD). Avadomide induced type I 
and II interferon (IFN) signaling in patient T cells, triggering a feedforward cascade of reinvigorated T 
cell responses. Immune modeling assays demonstrated that avadomide stimulated T cell activation, 
chemokine expression, motility and lytic synapses with CLL cells, as well as IFN-inducible feedback 
inhibition through upregulation of PD-L1. Patient-derived xenograft tumors treated with avadomide 
were converted to CD8+ T cell-inflamed tumor microenvironments (TMEs) that responded to anti-PD-
L1/PD-1-based combination therapy. Notably, clinical analyses showed increased PD-L1 expression on 
T cells, as well as intratumoral expression of chemokine signaling genes in B cell malignancy patients 
receiving avadomide-based therapy. These data illustrate the importance of overcoming a low 
inflammatory T cell state to successfully sensitize CLL to checkpoint blockade-based combination 
therapy. 
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Introduction 
 
Immune checkpoint blockade has demonstrated that reinvigorating anti-tumor immune activity can 
induce durable responses across multiple cancer types.1,2,3 PD-1 is expressed by T cells following 
activation and remains on exhausted T cells within a chronic inflammatory environment. PD-1 transmits 
inhibitory signals into T cells at the immunological synapse following engagement with its ligands PD-
L1 or PD-L2 expressed on tumor cells or APCs.4 Constitutive expression of PD-1 ligands through genomic 
amplification is seen in HL.5 In addition, pro-inflammatory cytokines including IFN-g contribute to PD-
L1 expression in the TME.2 Blocking the interaction of PD-1 with its ligands prevents inhibitory signaling 
and allows tumor-specific T cells to remain activated against tumor cells. The most promising clinical 
responses to PD-1 blockade have been seen in HL.5,6 However, the efficacy of anti-PD-1 immunotherapy 
in NHLs including diffuse large B-cell lymphoma (DLBCL) has been more modest.7 Unexpectedly, no 
activity was seen in a trial of anti-PD-1 therapy for R/R CLL,8 even although PD-L1-PD-1-mediated T cell 
dysfunction has been described.9-11 This clinical experience suggests that profound immunosuppressive 
barriers operate within the TME.  
Clinical activity of checkpoint inhibitors in cancer has been correlated with reduced disease 
burden,12 strong PD-L1 expression in the TME,5,13,14 tumor neoantigen load,15 and mutations in antigen 
presentation and IFN-g pathways.16-18 Additional studies have implicated T cell state including the 
number of tumor-infiltrating cytotoxic CD8+ T cells,19 as well as IFN-g response immune signatures.20,21 
Strong expression of PD-L1 is thought to reflect active anti-tumor T cell activity and represent a marker 
of adaptive IFN-inducible immune resistance,19 that characterizes T cell-inflamed microenvironments.22 
However, studies suggest that PD-L1 expression in the CLL TME is relatively low.8,10,23,24 Furthermore, 
although CLL cells are capable of responding to IFN-g and their MHC molecules are intact,9,25 a low 
frequency of neoantigen generation26,27 likely fosters poor tumor immunogenicity. In addition, CLL cells 
express low levels of adhesion and costimulatory molecules required for effective immune 
recognition.28,29 T cell dysfunction in CLL has been linked to tumor-induced cytoskeletal 
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reprogramming,30 and a defective ability to migrate31,32 and form immune synapses.9,29,33 Thus, 
identifying effective therapies capable of re-establishing immune effector functions could offer hope 
for R/R patients, as well as deepen targeted agent-induced responses.34  
Avadomide (CC-122) is a cereblon E3 ligase modulator (CELMoD) drug that has demonstrated 
clinical activity in DLBCL.35 Avadomide, like the immunomodulatory drug lenalidomide, binds to the 
protein target cereblon, a substrate receptor in the cullin4 E3 ligase complex, that promotes 
recruitment, ubiquitination and subsequent proteasomal degradation of the hematopoietic 
transcription factors Aiolos and Ikaros.36,37 Mechanistically, avadomide triggers an IFN response in 
DLBCL cells that induces direct tumor apoptosis.38 In contrast, avadomide is not directly cytotoxic to 
CLL cells, but has been reported to possess anti-proliferative activity.39 Advantageously, degradation of 
Aiolos and Ikaros in T cells by CELMoDs derepresses IL-2 transcription and production – leading to 
activation.38,40 The ability of avadomide to directly inhibit tumor cells while stimulating immune cells, 
suggests that it could represent a complementary treatment partner for checkpoint blockers.  
Here, we demonstrate that avadomide induces type I and II IFN signaling in previously 
exhausted patient T cells using CLL as a model B cell malignancy. Our studies reveal that the ability of 
this immunomodulatory drug to stimulate this immune compartment triggers a potent cascade 
reaction, that pairs effectively with PD-L1/-PD-1 axis blockade, leading to enhanced T cell-mediated CLL 
killing.  
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Methods 
Patient samples. All patient and age-matched healthy samples were obtained after written informed 
consent, in accordance with the Declaration of Helsinki and approved by the National Research Ethics 
Committee. All CLL samples (n=138) were previously untreated and selected to represent the 
heterogeneity of the disease. In vivo avadomide and obinutuzumab (CC-122-CLL-001; NCT02406742; 
ClinicalTrials.gov) and ibrutinib-based therapy samples (E1912; NCT02048813) came from review 
board-approved clinical trials.  
 
Antibodies/drugs. Avadomide, nivolumab (anti-PD-1) and durvalumab (anti-PD-L1) were provided by 
Bristol-Myers Squibb. Checkpoint blocking antibodies were used at 10 µg/mL. Avadomide 
(reconstituted in DMSO) was used at 0.5 µM final concentration unless otherwise stated (supplemental 
Methods). Specific doses were optimized for each immune modeling assay depending on the duration 
of treatment and addition of anti-CD3 + anti-CD28 T cell receptor (TCR) stimulation. Vehicle treated 
cells were cultured with DMSO alone or isotype control antibodies.  
 
Statistical analysis. Normality was assessed using the Shapiro-Wilk test. Paired t test (parametric) or 
Wilcoxon signed-rank test (non-parametric) were used to compare paired measurements between 2 
experimental groups. Alternatively, unpaired t test (parametric) or Mann-Whitney test (non-
parametric) were used to compare unpaired measurements between 2 experimental groups. Multiple 
group comparisons were performed using a 1-way or 2-way ANOVA test (unpaired, parametric) or a 
repeated-measures ANOVA with a Tukey’s multiple comparisons test (paired data, parametric). For 
non-parametric datasets, multiple group comparisons were performed using a Kuskal-Wallis test 
(unpaired data) or a Freidman test with Dunn’s multiple comparisons test (paired data). P < .05 was 
considered statistically significant. Statistical analysis was performed using GraphPad Prism.  
 
Additional methods can be found in the supplemental Methods. 
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Results 
 
Anti-PD-L1 is superior to anti-PD-1 but both elicit only partial anti-CLL T cell responses 
In order to better understand the activity of immunotherapy, we first modeled the capability of 
checkpoint inhibitors alone to break T cell tolerance against autologous CLL cells using a quantitative 
cytotoxicity assay. Anti-PD-1 antibody treatment triggered a small but non-significant improvement in 
T cell killing function when compared to vehicle treatment (Figure 1A). We confirmed that PD-1 was 
expressed by a proportion of both unstimulated and stimulated patient CD4+ and CD8+ T cells (Figure 
1B and Supplemental Figure 1A).29,41 Interestingly, this analysis revealed that patient T cell populations 
also expressed PD-L1, that increased significantly following stimulation (Figure 1C and Supplemental 
Figure 1A). PD-L1 positivity on baseline CLL cells was in agreement with previous reports.9,10 This led us 
to model the anti-CLL effect of anti-PD-L1 antibody treatment, that showed significantly increased CLL 
death compared with vehicle treated patient cells (Figure 1A). However, although anti-PD-L1 was 
superior to anti-PD-1 at eliciting anti-CLL T cell activity, both treatments only partially reactivated 
patient T cell killing function when compared to the cytolytic activity of healthy donor T cells. 
Given the relevance of the lymphoid TME for the regulation of immune surveillance42 and 
response to therapy,43 we next examined the PD-L1-PD-1 axis in an independent cohort of lymph node 
tissues from CLL and small lymphocytic lymphoma (SLL) patients using multicolor microscopy with 
image analysis (Figure 1D,E and Supplemental Table 1). We first analyzed non-malignant reactive lymph 
node tissues and identified PD-1+ cells as CD4+ T cells within germinal centers (likely T follicular helper 
cells),44,45 as well as a proportion of interfollicular PD-1+ CD4+ and PD-1+ CD8+ T cells (Figure 1D). In 
CLL/SLL, CD4+ T cells showed a diffuse localization pattern with increased numbers compared to CD8+ 
T cells. PD-1 expression was detected on both CD4+ and CD8+ T cells in CLL/SLL, with increased 
percentage positivity compared to interfollicular T cells from reactive tissues (Figure 1D and 
Supplemental Figure 1B). Unexpectedly, we detected the majority of PD-L1 expression on a proportion 
of CD4+ and CD8+ T cells in both reactive (marginal/interfollicular zone) and CLL/SLL tissues (Figure 1E 
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and Supplemental Figure 1B). Interestingly, we detected increased PD-L1 expression on CD8+ T cells in 
CLL patients with Richter’s transformation (RT-CLL) (Supplemental Figure 1B), who have shown better 
responses to anti-PD-1 monotherapy.8 In contrast, we detected weak PD-L1 expression on CLL tumor 
cells, consistent with previous reports.8,44,46 Notably, we observed that PD-1- and PD-L1-expressing T 
cells often exhibited close proximity interactions in CLL/SLL (3D volume rendered confocal images, 
Figure 1D,E). Taken together, our data suggests that a “noninflamed” microenvironment47 in CLL, 
incorporating sparse CD8+ T cell numbers, low PD-L1 expression and profound T cell exhaustion, will 
need to be overcome with additional immunostimulatory therapy in order to improve checkpoint 
blockade immunotherapy. 
 
Treatment with avadomide stimulates T cell immune synapses with a concomitant increase in PD-L1 
expression 
We first examined the ability of patient T cells to form synapses48 with tumor cells following avadomide 
treatment. We found that avadomide enhanced the number of CD4+ or CD8+ T cells recognizing CLL 
cells (Figure 2A) and increased the formation of T cell F-actin immune synapses (Figure 2B,C). We 
further revealed that avadomide treatment increased tyrosine-phosphorylated proteins49 at T cell 
synapses with CLL cells (Figure 2D,E). Notably, avadomide was significantly more potent at activating 
patient T cell synapses in comparison to lenalidomide treatment (Supplemental Figure 2A). In keeping 
with this enhanced immunostimulatory effect, avadomide augmented the degradation of Aiolos and 
Ikaros in T cells - the dominant immunomodulatory mechanism of action of these drugs (Supplemental 
Figure 3A-E).38,40 Immunophenotyping revealed increased expression of activation markers, particularly 
CD25 on avadomide-treated patient CD8+ T cells (Figure 2F and Supplemental Figure 2B,C). Notably, 
avadomide also increased expression of the costimulatory B7 family member CD86 on CLL cells. Co-
treatment of both CLL and T cells contributed to improved synapse interactions when compared to the 
treatment of patient T cells alone (Supplemental Figure 2D). Intriguingly, avadomide reduced the 
number of patient CD4+ and CD8+ T cells expressing PD-1, that could reflect a reversal of exhaustion 
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status (Figure 2G). In contrast, we detected increased PD-L1 expression on both T cell subsets and CLL 
cells following treatment (Figure 2H). Microscopy revealed that both PD-L1 and PD-1 exhibited 
enhanced polarized expression at T cell synapses following avadomide treatment (Figure 2I). This led 
us to evaluate the effect of treating patient T cells with avadomide plus PD-1 or PD-L1 inhibition on 
synapse signaling.48,50 Immunoblotting showed these combination therapies resulted in increased 
phosphorylation of the early TCR signaling molecules ZAP-70 and LAT compared to avadomide 
treatment alone (Figure 2J and Supplemental Figure 2E). AKT and MAPK that regulate signal 
transduction to the nucleus, also showed elevated activation with combination therapy. Taken 
together, the ability of avadomide to promote immune recognition led us to investigate its pairing with 
PD-L1/PD1 blockade for modulating anti-tumor effector activity.  
 
Anti-PD-L1/PD-1-mediated anti-tumor T cell function can be enhanced when combined with 
avadomide 
Cytotoxicity assays revealed that treating patient T cells and autologous CLL cells with avadomide 
activated anti-tumor T cell killing function (Figure 3A), with enhanced potency compared to 
lenalidomide (Supplemental Figure 4A). However, combining avadomide with anti-PD-1 or anti-PD-L1 
resulted in more CLL killing when compared to these drugs alone (Figure 3A, Supplemental Figure 4B 
and Supplemental Table 2), with effector activity comparable to healthy donor T cell controls. In 
addition, combination therapy was more effective at promoting T cell-mediated killing of DLBCL 
compared to avadomide alone (Supplemental Figure 4C). Cell conjugation assays confirmed that 
avadomide promoted formation of granzyme B+ T cell lytic synapses with autologous malignant B cells 
in both DLBCL (Figure 3B,C) and CLL (Supplemental Figure 4D). Treating CLL cells alone with avadomide 
or lenalidomide confirmed that these drugs were not directly cytotoxic to these tumor cells 
(Supplemental Figure 4E). Notably, we found that treatment of both T cells and CLL cells with 
avadomide induced maximum killing compared to treating T cells alone (Figure 3D), suggesting that the 
ability of avadomide to enhance CLL APC function (Supplemental Figure 2C,D), contributes to anti-CLL 
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T cell activity. Given our earlier observations, we also investigated the contribution of T cell-expressed 
PD-L1 to checkpoint blockade activity. We found that treating patient T cells alone with anti-PD-L1 
triggered significant anti-CLL T cell killing; albeit at a reduced level compared to the co-treatment of 
tumor cells (Figure 3D). This data challenges a prevalent view that tumor cells are the primary source 
of PD-L1 during immunosuppressive signaling.  
Finally, we investigated the ability of avadomide and its combination with anti-PD-1 or anti-PD-
L1 to activate T cells from patients who had received prior ibrutinib-based therapy for 12 months,34 as 
this BTK inhibitor is known to modulate immune responses.51 We found that avadomide alone or its 
combination with checkpoint blockers enhanced the anti-CLL killing function of ibrutinib-rituximab-
exposed T cells (Figure 3E), consistent with our treatment-naïve patient data. Collectively, our results 
demonstrate that the pairing of avadomide with PD-L1/PD-1 blockade can effectively reactivate 
previously exhausted patient T cells. 
 
Avadomide induces a type I and II IFN gene signature in patient T cells 
Next, RNA-Seq was performed on purified patient T cells from treatment naïve CLL patient samples 
treated with avadomide or anti-PD-1 or anti-PD-L1 alone or in combinations. Patient samples were 
selected to represent extremes of prognosis (n=6 favorable and n=6 poor prognostic baseline markers 
including TP53 abnormalities, Supplemental Table 3). Differential expression pathway analysis revealed 
that the top functional gene categories common for all the avadomide and combination treated patient 
samples (independent of checkpoint inhibition alone) were related to the response to both type I and 
II IFN signaling, as well as inflammatory TNF-a, IL-6/JAK/STAT3 and IL-2/STAT5 signaling responses 
(Figure 4A and Supplemental Figure 5A). Transcription factor enrichment analysis showed that 50% of 
all differentially expressed genes following avadomide treatment were significantly associated with 
Ikaros control (Supplemental Figure 5B), in keeping with the mechanism of action of this CELMoD. 
Pathway analysis revealed a strong enrichment of genes involved in proliferation, cytokine and 
chemokine signaling, F-actin polymerization, T cell differentiation and costimulation (Figure 4B, 
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Supplemental Figure 5C and Supplemental Table 5). Notably, avadomide induced the expression of IFN 
type I and II-inducible chemokines Cxcl9, Cxcl10 and Cxcl11,52 that are part of an immune-related gene 
expression signature predictive of favorable response to PD-1 blockade in solid cancer (Supplemental 
Figure 5D).20 In addition, IFN-induced counter-regulatory pathways including Cd274 (PD-L1), Lag3 and 
Ido1 were upregulated by avadomide. Avadomide and the combination treatments induced IFN 
signaling within patient T cells in both good and poor prognostic CLL subtypes (Figure 4C), whereas 
none of these response genes were significantly upregulated with anti-PD-1 or anti-PD-L1 alone. In 
contrast, E2F- and Myc-related gene targets linked to cell cycle and metabolic activation53,54 were 
among the T cell transcriptome changes following checkpoint inhibition alone (Supplemental Table 6). 
Given the above observations, we next asked whether deregulated IFN gene signatures were associated 
with T cell dysfunction in treatment naïve CLL. Our analysis of a comparative gene expression profiling 
dataset30 revealed that patient CD4+ T cells showed signatures suggestive of perturbed type I and II IFN 
signaling compared to age-matched healthy donor T cells. These IFN signatures were in common with 
those regulated by avadomide but in opposing directions (Figure 4D). Further analysis revealed that 
CD8+ T cells from treatment naïve CLL showed deregulated IFN-a, costimulation, chemokine, motility 
and effector pathways, that again were oppositely regulated by avadomide treatment. Thus, these 
results support the ability of avadomide to normalize dysfunctional IFN and chemokine responses in 
patient T cells that are linked to anti-tumor immunity.55  
 
Avadomide induces an inflammatory T cell secretome and motility 
The above data led us to investigate whether avadomide promoted the release of proinflammatory 
mediators within the T cell secretome. Antibody arrays revealed that avadomide, as well as its 
combination with anti-PD-1, induced the secretion of several proinflammatory (IL-2, TNF-a) and 
chemotactic cytokines (CXCL10, CCL5) (Figure 5A,B). In contrast, anti-PD-1 alone had little impact on 
the production of cytokines from patient T cells. In keeping with our transcriptome data, multiplex 
immunoassays confirmed the consistent enrichment of immunoregulatory and chemoattractant 
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cytokines including CXCL1056,57 within the culture supernatants of T cells treated with avadomide alone 
or in combination with anti-PD-1 or anti-PD-L1 (including significantly increased CXCL10 production 
with combination therapy compared to avadomide alone) (Figure 5C). We next assessed the impact of 
treatment on T cell migration.31,32 Time-lapse microscopy assays showed that avadomide, as well as 
anti-PD-1 or anti-PD-L1 alone, enhanced T cell motility compared to vehicle treatment (Figure 5D). 
However, compared to these drugs alone, avadomide plus anti-PD-1 or anti-PD-L1 increased T cell 
migration rates. We next hypothesized that a chemokine-enriched secretome could attract additional 
T cells. To test this, we collected the culture supernatants of avadomide-treated patient T cells and 
performed chemotaxis assays with untreated autologous T cells. The conditioned media of avadomide-
treated T cells increased the recruitment of T cells, which was further enhanced when avadomide was 
paired with PD-L1/PD-1 blockade (Figure 5E). This augmented T cell migration was reduced by co-
treating patient T cells with a neutralizing antibody targeting CXCR3, the receptor for CXCL9-11 (Figure 
5F). Collectively our data suggest that the ability of avadomide to activate IFN-activated chemokine and 
cytoskeletal signaling in patient T cells could enhance the recruitment and functionality of immune cells 
in the TME.  
 
Therapeutic avadomide plus anti-PD-L1 therapy reduces established tumor burden in patient-derived 
xenografts  
Next, we tested the immunomodulatory and anti-tumor activity of avadomide and checkpoint blockade 
using a patient-derived xenograft model. CLL cells and T cells engraft in the murine spleen and have 
been shown to effectively model the lymphoid TME and activated signaling pathways.58,59 This human-
based in vivo model was chosen as murine cereblon is known to be resistant to CELMoD-mediated 
Aiolos and Ikaros degradation.60 Mice with established tumors (3 weeks post-xenografting) were 
treated with a single dose of avadomide or anti-PD-L1 alone or in combination for 6 days. We firstly 
measured the impact of these treatments on T cell activation within the splenic TME and found that 
the percentage of CD25+ CD8+ T cells increased following avadomide and combination anti-PD-L1 
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therapy (Figure 6A). In contrast, this stimulatory effect was less evident in the patient CD4+ T cell 
compartment (Supplemental Figure 6A). Notably, avadomide therapy increased the frequency of PD-
L1+ CD8+ T cells and CLL cells (Figure 6B and Supplemental Figure 6C), whereas expression of PD-1 did 
not change (Supplemental Figure 6B).61,62 Confocal microscopy corroborated the ability of avadomide 
to induce PD-L1 expression within the immune TME (Figure 6C) and triggered CD8+ T cells to increase 
in number and infiltrate tumor areas more vigorously (Figure 6D). We found that CD4+ T cells localized 
mainly within CLL nodules at baseline (vehicle) intermixed with tumor cells, in keeping with their pro-
tumor role.58 In contrast, CD8+ T cells exhibited a tumor-excluded localization pattern at baseline that 
converted to a tumor-infiltrated pattern following avadomide treatment, maximally augmented with 
combination therapy. Avadomide and its pairing with anti-PD-L1 significantly increased the percentage 
of CD8+ T cells infiltrating spleen tissues (Supplemental Figure 6D). In addition, proliferation assays 
confirmed that avadomide increased T cell expansion, with the highest fraction of proliferating cells 
detected in the CD8+ compartment, particularly with combination therapy (Supplemental Figure 6E). In 
contrast, we confirmed that avadomide exhibited anti-proliferative activity in CLL cells that was 
detected between 4-6 days in a long-term co-culture model but was not directly cytotoxic to tumor 
cells (Supplemental Figure 7A-C).39 In harmony with our earlier data, we detected increased CXCL10 
and CXCR3 expression on infiltrating CD8+ T cells following avadomide therapy (Figure 6E). 
Immunofluorescent scanning revealed a marked increase in CD8+ T cells within the splenic TME 
following avadomide and combination therapy (Figure 6F). We also found that CD8+ T cells from 
avadomide- or combination therapy-treated tumors showed a higher expression of granzyme B+ 
cytolytic cells (Figure 6G).63,64 Importantly, in all patient samples tested (Supplemental Table 4), 
avadomide plus ant-PD-L1 combination therapy resulted in greater tumor reduction than did either 
treatment alone (Figure 6H-J). Notably, the xenograft model was refractory to anti-PD-L1 monotherapy. 
We also demonstrated that avadomide plus anti-PD-1 showed comparable anti-CLL efficacy to anti-PD-
L1 combination therapy (Supplemental Figure 6F). Lastly, we tested whether the activity of avadomide 
was dependent on the presence of CD8+ T cells. Prior depletion of these cytolytic cells prevented the 
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ability of avadomide plus anti-PD-L1 to trigger autologous CLL killing (Supplemental Figure 6G). Taken 
together, although we demonstrate relevant anti-proliferative activity against CLL cells, we believe both 
our in vitro and in vivo data effectively model the ability of avadomide to stimulate cytotoxic T cell 
activity. The above in vivo results support the concept that triggering IFN-driven T cell responses with 
avadomide could convert noninflamed CLL tumors into CD8+ T cell-inflamed ones, that could then 
respond to checkpoint blockade therapy.   
 
Avadomide-based therapy triggers T cell activation and intratumoral chemokine signaling in DLBCL 
Finally, to validate our preclinical findings, we compared the expression of T cell co-signaling molecules 
in pre-treatment and early on-treatment peripheral blood samples from R/R CLL patients treated with 
avadomide plus obinutuzumab therapy (Supplemental Figure 8). Although only a small number of 
patient samples were available and hence our analysis could not reach the threshold of statistical 
significance, our immunophenotyping showed a trend for avadomide-based therapy to increase PD-L1 
expression, as well as the CD28-superfamily member ICOS on T cells (Figure 7A,B), that localized to 
repaired T cell synapses (Figure 7C). In contrast, PD-1 expression on CD8+ T cells showed a decreased 
trend with therapy. We further examined intratumoral chemokine signaling using RNA-seq data from 
paired pre-treatment and on-treatment (2 weeks) tumor biopsies from patients with R/R DLBCL treated 
with avadomide monotherapy (CC-122-ST-001; NCT01421524).35 We examined the expression level of 
a set of 61 chemokine signaling genes that were selected based on our earlier pathway analysis of 
avadomide-treated patient T cells (Figure 4). The intratumoral expression of all 61 genes including 
chemokines Cxcl9-11 increased in avadomide on-treatment biopsies compared to screening, of which 
31 genes were significantly enriched (Figure 7D). Thus, these clinical immune and tumor monitoring 
results indicate that avadomide is an effective drug to stimulate IFN-response signatures in B cell 
malignancy. 
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Discussion 
 
Our study provides evidence that CLL can harbor noninflamed TMEs that are defined by a paucity of 
pre-existing cytolytic CD8+ T cells and low expression of PD-L1.1,22,47 This could help explain why anti-
PD-1 therapy alone failed to clinically (re)-activate anti-CLL T cell activity.8 PD-L1 expression on tumor 
cells5 and unexpectedly on immune cells,65 can be predictive of response to checkpoint inhibitors across 
tumor types. Notably, we show that PD-L1, as well as PD-1, are predominately expressed by a 
proportion of T cells in the immunosuppressive CLL TME, rather than on tumor cells. Interestingly, 
targeting T cell-associated PD-L1 enhanced their cytolytic activity and migratory function. These 
findings indicate that T cell PD-L1 signaling in cis66,67 and/or in trans between surrounding T cells and 
CLL cells,23,68,69 contributes to the negative regulation of T cell responses in CLL, in addition to the known 
interactions of PD-1+ T cells with PD-L1+ tumor and other TME cells.9,70,71 However, in vitro and in vivo 
assays showed that anti-PD-1 and anti-PD-L1 monotherapies were largely ineffective at overcoming T 
cell tolerance in CLL.  
Importantly, our study reveals that avadomide represents a candidate for combination therapy 
with PD-L1/PD-1 axis blockade. Through in vitro and in vivo mechanistic studies, we demonstrate that 
avadomide reprograms patient T cells by triggering IFN-inducible activated T cell biology gene 
signatures, which complement PD-L1/PD-1 blockade. Our studies reveal that avadomide stimulates the 
proliferation and release of chemokines by T cells which can recruit additional CD8+ T cells, upregulates 
PD-L1 in the immune TME and enhances T cell lytic synapse formation. When combined with 
therapeutic anti-PD-L1, we detected enhanced activation of cytotoxic CD8+ T cells in treated patient-
derived xenograft tumors, resulting in tumor shrinkage. Notably, we find that CLL patients receiving 
avadomide-based therapy show increased expression of PD-L1 on circulating T cells, confirming our 
laboratory findings that avadomide unleashes IFN responses in this immune compartment. We also 
show that avadomide can induce intratumoral chemokine gene expression in treated DLBCL patients, 
further supporting the induction of IFN-inducible biology. Clinical correlative studies of avadomide 
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monotherapy in R/R DLBCL have shown pharmacodynamic effects on T cell activation and trafficking 
within the TME, consistent with our CLL model dataset.35 Interestingly, T cell-rich DLBCL TMEs at 
baseline correlated with improved outcome, highlighting the relevance of immune cells for CELMoD 
activity. Notably, avadomide has been shown to induce IFN-stimulated genes in DLBCL tumor cells 
resulting in their apoptosis.38 In contrast, we show that  avadomide has an anti-proliferative effect on 
CLL cells but did not induce direct tumor B cell apoptosis. Blocking proliferation is likely to be a direct 
IFN-a signaling effect in CLL tumor cells; however, this concept was not pursued in this study. Instead, 
we reveal for the first time that avadomide can elicit both type I and type II IFN-induced inflammatory 
signaling in previously exhausted patient T cells. Ikaros has been shown to be a critical repressor of the 
gene program associated with the response to type I IFN in mature T cells using  a knock-out murine 
model, that is in keeping with our data revealing the ability of  avadomide to derepress type I IFN and 
inflammatory signaling in previously exhausted patient T cells. In contrast, predominantly type II IFNg-
associated T cell responses have been reported for lenalidomide treatment,72 that could reflect the 
reduced depth of Ikaros degradation induced by this immunomodulatory drug compared with 
avadomide. Our data using avadomide supports the concept of therapeutically reshaping noninflamed 
CLL and NHL tumors into T cell-inflamed TMEs,22,56 that could engage both innate and adaptive 
immunity, to overcome resistance to checkpoint blockade. There is substantial evidence demonstrating 
that type I and II IFN signaling is required within TMEs to prevent development of an 
immunosuppressive state.73,74 In line with impaired IFN signaling in T cells representing a common 
immune defect in cancer,75 our analysis of T cells from treatment naïve CLL patients showed that they 
express deregulated IFN type I and II signaling genes compared to healthy age-matched control T 
cells.30,76 Our study supports the ability of avadomide to normalize dysfunctional IFN signaling, 
chemokine expression and cytotoxic effector gene pathways in previously exhausted patient T cells.   
These insights should facilitate the development of optimal combination therapies of CELMoDs 
or other IFN-inducing drugs, such as STING agonists,77,78 with checkpoint inhibitors. There is a growing 
appreciation of the importance of IFN signaling in the TME and response to chemotherapy, 
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radiotherapy, as well as immunotherapy.18,20,21,74,79 However, although mimicking an IFN-induced anti-
viral state in tumors appears attractive, it is important to note, that studies are also revealing that IFNs 
can act as double-edged swords, promoting both feedforward and feedback inhibitory mechanisms.80 
Persistent IFN signaling in chronic virus infections and cancer can be immunosuppressive by inducing 
PD-L1, IDO and LAG-3.80,81 Our transcriptome and functional data revealed that avadomide induced 
these negative-feedback molecules including increased PD-L1 expression on re-activated T cells and 
CLL cells. Our in vitro and in vivo data demonstrated improved anti-CLL efficacy when avadomide was 
combined with PD-L1/PD-1 blockade, supporting combination approaches that bypass IFN-induced 
negative feedback and optimally activate cytolytic T cells. Type I IFN modulating drugs and lenalidomide 
have shown efficacy against hematological malignancies but a major barrier has been dose-limiting 
toxicity.36,74,82,83 Notably, an increased incidence of severe adverse events including deaths has been 
associated with the combination of immunomodulatory drugs with anti-PD-1 in multiple myeloma.84,85 
This clinical experience underscores the risks of developing combination immunotherapy for 
hematological tumors, as well as the requirement for optimal trial design when testing 
immunomodulatory agents. However, the lack of clinical activity of anti-PD-1 monotherapy in NHL7 and 
CLL,8 has highlighted the need to incorporate checkpoint blockade therapies into more powerful 
combinations to unleash the power of anti-tumor immune cells, with potential therapeutic partners 
including CELMoDs and immunomodulatory drugs, CAR T cells and bispecific antibodies.86,87 The field 
will have to carefully manage the expected toxicity of activating anti-tumor immune responses, as well 
as the direct and indirect effects of these powerful therapies on malignant B cells within lymphoid 
TMEs, that can all contribute to serious immune-related adverse effects and cytokine release syndrome 
in patients. It may be that CELMoDs will work best with carefully timed dosing to avoid inducing chronic 
IFN signaling that could promote suppressive or refractory mechanisms within the immune TME80 and 
in a tumor debulked or lower burden scenario.88 Combining checkpoint blockade with 
avadomide/CELMoDs could represent a powerful combination strategy for deepening targeted drug 
(e.g. BTK inhibitor)-induced responses51,89 and working towards curative therapy in CLL.3 Defining CD8+ 
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T cell/immune cells, checkpoints and IFN-associated signatures within the immune TME could 
represent important correlative biomarkers for predicting and monitoring activity, toxicity and 
resistance.1,81,90 Collectively, this pre-clinical study using CLL as a model B cell malignancy, provides 
proof of concept that inducing inflammatory IFN type I and II signaling in patient T cells can successfully 
reshape anti-tumor T cell responses and sensitize CLL to immune checkpoint blockade. 
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Figure Legends 
 
Figure 1. Partial T cell responses to anti-PD-1 or anti-PD-L1 alone and evidence of a noninflamed TME 
in CLL. (A) Autologous T cell killing function against patient CLL cells pulsed with superantigen (sAg) 
(target cells) (n=10) as detected by cytotoxicity assays following treatment with isotype control Ab, anti-
PD-1 or anti-PD-L1 blocking Abs. Data presented as mean ± SEM. Aged-matched healthy donor T cell 
activity against autologous B cells pulsed with sAg (target cells) was included as controls. Percentage 
positive PD-1+ cells (B) and PD-L1+ cells (C) on unstimulated or anti-CD3 + anti-CD28 stimulated patient 
T cells (CD4+, CD8+) (n=19). PD-L1 expression on freshly isolated CD5+ CD19+ CLL cells is also shown in 
C. Representative multispectral immunofluorescence images of non-malignant reactive (n=5) or 
CLL/SLL (n=34) lymph node FFPE biopsy tissues for (D) PD-1 (white) and (E) PD-L1 (white) expression on 
T cells (CD4, red and CD8, green) and B cells (CD20, blue). Original magnification, 20X medial optical 
section images (far left panels, scale bar = 100 µm), cropped images (middle two panels, scale bars = 
50 µm) and 3D volume rendered confocal images of intercellular PD-1+ or PD-L1+ T cell interactions (far 
right panels) (cropped, 20X images). **P < .01; ns: not significant using a repeated measures one-way 
ANOVA with Tukey's multiple comparisons test (or an unpaired t test for comparing CLL T cell activity 
with healthy donor T cells) (A) and Wilcoxon signed-rank tests for comparisons between 
unstimulated and stimulated T cell subsets (B, C). Data presented as mean ± SEM. 
 
Figure 2. Avadomide activates previously exhausted CLL patient T cells and induces expression of PD-
L1. (A) Intercellular autologous CD4+ or CD8+ T cell:tumor cell conjugates formed from vehicle or 
avadomide treated CLL patient samples (n=25). Image analysis data presented as mean % T cell:CLL 
conjugates ± SEM. Representative confocal images show patient T cell:CLL cell (blue) conjugate F-actin 
(red) interactions after treatment. Original magnification, 63X (scale bars: 10 µm). (B) Representative 
medial optical section (scale bars: 5 µm) and 3D volume rendered images of CD8+ T cell conjugates with 
increased F-actin (red) immune synapse formation with CLL tumor cells (arrow) following avadomide 
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treatment. Relative recruitment index, RRI image analysis of F-actin (red) (C) and tyrosine-
phosphorylated protein (D) polarization in autologous CD4+ or CD8+ T cell:CLL conjugates following 
vehicle or avadomide treatment (n=30). (E) Representative 3D volume rendered images of CD8+ T cell 
conjugates showing increased phosphotyrosine signal (white, pTyr) at synapses with avadomide. (F) 
Representative flow cytometric histograms of CD25 and CD69 (upper plots) and HLA-DR (lower panel) 
expression on stimulated patient CD8+ T cells with treatment (n=5). CD86 expression on treated CD5+ 
CD19+ CLL cells is also shown. Frequency of PD-1 (G) and PD-L1 (H) expressing cells (stimulated CD4+ 
(blue), CD8+ (red) or CD5+ CD19+ CLL cells (black)) following avadomide treatment (n=19). (I) 
Representative 3D volume rendered images of CD8+ T cell:tumor (blue) conjugates showing reduced 
and increased expression of PD-1 (white) and PD-L1 (green) respectively, with both molecules polarizing 
at synapses with avadomide. (J) Representative immunoblots of pre-treated (as indicated), stimulated 
patient T cells subsequently conjugated with MEC-1 tumor cells (T cell:tumor cell conjugates, 5 and 15 
min for early and late conjugation times respectively) probed for the phospho (p)-proteins  p-ZAP-70, 
p-LAT, p-MAPK and p-AKT (n=3). **P < .01 using Wilcoxon signed-rank tests (A, C, D, G, H). Data 
presented as mean ± SEM 
 
Figure 3. Pairing anti-PD-L1/PD-1 with avadomide effectively reactivates anti-CLL T cell killing function. 
(A) Illustration of the autologous cytotoxicity assay using treated patient T cells mixed with treated CLL 
cells and flow-based quantification of T cell killing function against superantigen (sAg)-pulsed CLL cells 
as target cells (mean % CLL cell death ± SEM for n=10 patients) following the treatments indicated. 
Aged-matched healthy donor T cell effector activity against autologous B cells loaded with sAg (as target 
cells) was included as a control. (B) Representative confocal images showing CD8+ tumor-infiltrated 
lymphocytes (TILs) forming granzyme B+ (Gzmb, green), F-actin (red) lytic synapses with primary 
autologous DLBCL tumor cells (blue) with avadomide treatment (non-tumoricidal dose) (co-localization 
signal: yellow) (original magnification 63X, scale bars: 5 µm). (C) Relative recruitment index, RRI image 
analysis of Granzyme B (green) polarization in autologous CD8+ TIL:DLBCL conjugates following vehicle 
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or avadomide treatment (n=5). (D) Autologous T cell killing function against patient CLL cells (n=10) 
following treatment of patient T cells alone (prior to mixing with untreated CLL cells) or treating both T 
cells and CLL cells. (E) T-cell mediated cytotoxicity against baseline autologous CLL cells using 12 CLL 
patient samples who had received ibrutinib-based therapy for 12 months. T cells and tumor cells were 
treated as indicated. *P < .05; **P < .01; ns: not significant using a repeated measures one-way ANOVA 
with Tukey's multiple comparisons test (A and E) (or an unpaired t test for comparing CLL T cell activity 
with healthy donor T cells), Wilcoxon signed-rank test (C) and 2-way ANOVA (D). Data presented as 
mean ± SEM. 
 
Figure 4. Avadomide induces IFN type I and II signaling in patient T cells encompassing activation, 
exhaustion and cytotoxicity and normalizes deregulated IFN and chemokine gene expression in 
previously exhausted T cells. (A) Top differential hallmark pathways between vehicle and avadomide 
treatment. Normalized enrichment scores (NES) represent the mean score over avadomide-treated 
samples, with positive scores indicating upregulation with avadomide treatment relative to vehicle 
control. (B) Heatmap of top immune pathways enriched by avadomide treatment, shown under 
multiple treatment conditions. Cell colors indicate mean NES for each pathway, indicating directionality 
and strength of the gene pathway changes. (C) Heatmap of selected IFN genes deregulated by 
avadomide treatment, shown under multiple treatment conditions for multiple patient subsets 
indicated. Cell colors indicate the mean log fold change of expression compared to vehicle control, with 
positive values (red) or negative values (blue) indicating upregulation or downregulation respectively 
compared to vehicle. (D) Barcode enrichment plot for a gene signature upregulated in age-matched 
healthy donor CD4+ T cells compared to CLL patient CD4+ T cells 
(GSE8835_HEALTHY_VS_CLL_CD4_TCELL_UP) that is significantly upregulated by avadomide 
treatment. This data supports normalization of deregulated IFN gene expression in previously 
exhausted patient T cells towards a healthy T cell transcriptome profile. 
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Figure 5. Avadomide and its combination PD-L1/PD-1 blockade induces an inflammatory T cell 
secretome and enhances T cell motility.  (A) Representative scanned dot blot from a cytokine array 
hybridized with culture supernatants from treated patient T cells. (B) Quantification of the secretome 
dot blots of conditioned media from treated patient T cells. Data shows the mean pixel intensity 
(representative of 3 patients). (C) Luminex FLEXMAP 3D cytokine bead array data shown as fold change 
(compared to untreated cells) for the indicated cytokines in treated patient T cell culture supernatants 
(n=10). (D) Representative migratory tracks of individual patient T cells are shown in the far-left plots. 
Bar charts show speed of T cell migration following the anti-PD-1-based (left) and anti-PD-L1-based 
(right) immunotherapy treatments indicated (n=6 patients, minimum of 15 cells per patient sample 
treatment). (E) Illustration of the chemotaxis assay of autologous T cells toward conditioned media 
(lower well) derived from avadomide treated patient T cells and quantification of autologous T cell 
migration towards treated T cell conditioned media (n=8). CXCL10 (lower well) included as an assay 
control. Data are presented as fold change relative to medium alone control. (F) Bar chart showing 
speed of patient T cell migration (n=3) following the drug treatments indicated and in the presence of 
anti-CXCR3 Abs were indicated. *P < .05; **P < .01; using a Freidman test with Dunn’s multiple 
comparisons test (C) and a repeated measures one-way ANOVA with Tukey's multiple comparisons test 
(D-F). Data presented as mean ± SEM. 
 
Figure 6. Therapeutic avadomide converts CD8+ T cell excluded (noninflamed) patient-derived 
xenografts into CD8+ T cell-inflamed tumors that respond to anti-PD-L1 combination therapy. (A) Flow 
cytometric percentage of patient CD8+ CD25+ T cells harvested from CLL patient-derived xenograft 
splenic TMEs following drug treatments (n=6 patient samples, 3-4 mice per patient sample treatment 
group) (B) Representative flow cytometric histograms of PD-L1 expression on patient CD4+, CD8+ T cells 
and CD5+ CD19+ CLL cells harvested from the splenic TME comparing vehicle (blue) and avadomide (red) 
treated mice. Representative multispectral immunofluorescence images of splenic TME tissue (n=6 
patient samples) from treated mice (C) for human CD20 (blue), CD8+ (green), CD4+ (red) patient T cells 
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and PD-L1 (white); (D) for human CD20 (blue), CD8+ (green) and CD4+ (red) patient T cells; (E) for human 
CD20 (blue), CD8+ (green), CXCL10 (red) and CXCR3 (white); (G) for human CD20 (blue), CD8+ (green), 
CD4+ (red) patient T cells and granzyme B (GZMB) (white). Original magnification, 20X medial optical 
section images (scale bar = 100 µm for C-E and 20 µm for G) and 3D volume rendered confocal images 
of intercellular PD-L1+ (C) or GZMB+ (G) CD8+ T cell interactions (white/green) with CLL cells (blue) with 
treatments (cropped, 20X images). (F) Representative large images acquired by an Olympus BX61VS 
fluorescence slide scanner (original magnification, 4X, scale bar = 200 µm) of splenic TME tissue (n=6 
patient samples) from treated mice for human CD20 (blue) and CD8+ (green) patient T cells. (H) CLL 
tumor burden in splenic TMEs. Flow cytometric percentage of human CD5+ CD19+ CLL cells of tissue 
splenocytes (total nucleated cells, human and murine) (n=6 patient samples, 3-4 mice per patient 
sample treatment group) analyzed from splenic TMEs following drug treatments. (I) Representative 
pictures of patient-derived xenograft splenic TME tissues. An established tumor (CLL PBMC engrafted 
spleen) in comparison to a non-diseased healthy murine spleen is shown (upper image). Xenograft 
splenic TME tissues are shown following different treatments (scale bar = 2 cm). (J) Weight of xenograft 
(n=3 patient samples) spleen TME tissues following drug treatments. *P < .05; **P < .01; ns: not 
significant using a repeated measures one-way ANOVA with Tukey's multiple comparisons test (A, H 
and J). Data presented as mean ± SEM. 
 
Figure 7. In vivo avadomide-based therapy effect on immune activation in peripheral blood and tumor 
biopsies. Immunophenotyping flow cytometric measurements for ICOS, PD-1 and PD-L1 positive CD8+ 
T cells (A) and CD4+ T cells (B) from the peripheral blood of CLL patients (n=7-9) treated with avadomide 
and obinutuzumab therapy. Cycle 2, day 15 and cycle 3, day 8 data are compared to baseline (screening 
blood samples analysis). (C)  Representative cropped medial optical section confocal images of CD8+ T 
cell conjugates with autologous CLL tumor cells (blue) showing increased ICOS (green) at F-actin (red) 
immune synapses with avadomide treatment. Original magnification, 63X (scale bars: 10 µm). (D) RNA-
seq was performed on paired lymph node tissue biopsies from 18 R/R DLBCL patients at screening 
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(baseline) and following avadomide therapy (on-treatment, Cycle 1, day 10/15) (clinical trial: 
NCT01421524). The heatmap shows the relative expression and significant enrichment (P < .05) of 
chemokine signaling pathway genes (KEGG_CHEMOKINE_SIGNALING_PATHWAY) following avadomide 
therapy in DLBCL. 
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